Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems

Shirbaghaee, Zeinab; Bolhassani, Azam

doi:10.1002/bip.22759

Cited by 113 publications

(92 citation statements)

References 208 publications

(220 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL‐4 and IL‐10 secreted by activated Th2 cells serve to promote B cell proliferation and differentiation into plasma cells, thus stimulating antibody production and assisting in the humoral immune response. HBc VLPs simulate the structure of natural viruses, as well as stimulate the natural immune response by activating pattern recognition receptors, which have the ability to induce a wide range of cell‐mediated immune responses . Notably, the secretion of IFN‐γ and IL‐2 in the rHBc/AO and rHBc/AOT VLP groups was significantly higher than that in the inactivated vaccine group ( P < .001).…”

Section: Discussionmentioning

confidence: 99%

Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Yao

Shao

Zhao

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Recently, many countries, including China, have experienced a series of type A and O foot‐and‐mouth disease virus (FMDV) epidemics, causing serious economic losses. Although concerns about the safety of inactivated FMD vaccines have been raised, the development of a safe and effective subunit vaccine is necessary. We constructed two chimeric virus‐like particles (VLPs; rHBc/AO and rHBc/AOT VLPs) displaying tandem repeats of B cell epitopes (VP1 residue 134‐161 and 200‐213) derived from type A and O FMDV and one T cell epitope (3 A residue 21‐35) using the truncated hepatitis B virus core (HBc) carrier. Our results indicate that the chimeric HBc can self‐assemble into VLPs with these FMDV epitopes displayed on the surface. Immunization with the chimeric VLPs induced specific IgG and neutralization antibodies against type A and O FMDV in mice. Compared with the commercial type A/O FMDV bivalent inactivated vaccine, rHBc/AO and rHBc/AOT VLPs significantly stimulated the production of Th1 type cytokines (IFN‐γ and IL‐2), whereas Th2 cytokine production (IL‐4 and IL‐10) was decreased. Compared with rHBc/AO, rHBc/AOT induced increased Th2 cytokine and specific IgG production. These results demonstrate that the VLPs constructed in the current study induced both humoral and cellular immune responses and may represent potential bivalent VLP vaccines targeting both FMDV type A and O strains.

show abstract

Section: Discussionmentioning

confidence: 99%

Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Yao

Shao

Zhao

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…However, the role of monocytes in regulating polio vaccine‐mediated immunity of healthy humans has not been fully known in detail. Recently, a systems biology approach was used to study innate and adaptive responses to vaccinations in humans with live‐attenuated vaccines for yellow fever vaccine, seasonal influenza, and Zika virus . The goal of a bioinformatical approach was to provide a comprehensive understanding of the biologic processes, which is essential for the development of effective immune responses.…”

Section: Discussionmentioning

confidence: 99%

Identification of genes and pathways in human antigen‐presenting cell subsets in response to polio vaccine by bioinformatical analysis

Wenyong

Liu

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Background Polio eradication has been achieved in the world except for three countries due to the widespread use of the inactivated poliovirus vaccine (IPV) and the live‐attenuated oral poliovirus vaccine. Following polio eradication, the IPV would be the only polio vaccine available. However, the mechanisms of the interactions between IPV and human antigen‐presenting cells (APCs) remain largely unclear. Methods To investigate the involvement of the IPV in human monocytes, we downloaded the gene chip GSE44721 from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the GEO2R analysis tool. Functional and pathway enrichment analyses were performed for DEGs using the Metascape database. DEG‐associated protein–protein‐interactions (PPIs) were established by the Search Tool for the Retrieval of Interacting Genes website and visualized by Cytoscape. Results There were 240 DEGs (51 upregulated and 189 downregulated genes) identified from the GSE44721 data set, and they were significantly enriched in several biological processes, including antigen processing and presentation of lipid antigen via MHC class Ib, adaptive immune response, and response to interferon‐gamma. One hundred thirty‐six nodes were screened from the DEG PPI network. There were six significant hub proteins (WDR36, MRTO4, RPF2, PPAN, CD40, and BMS1) that regulated the IPV in human monocytes. Conclusions In summary, using bioinformatical analysis, we have information for the immunization activated by the IPV in monocytes. Moreover, hormones and cytokines regulate the activation of APCs.

show abstract

“…The most common covalent bond was designed by the heterobifunctional chemical cross-linkers with amine and sulfhydryl-reactive arms (Shirbaghaee and Bolhassani, 2016;Hill et al, 2018). Antigens could be linked to VLPs through covalent or non-covalent bonds known as chimeric VLP (cVLPs) leading to the induction of immune responses against foreign protein epitopes.…”

Section: Vlps As Delivery Systemsmentioning

confidence: 99%

“…Antigens could be linked to VLPs through covalent or non-covalent bonds known as chimeric VLP (cVLPs) leading to the induction of immune responses against foreign protein epitopes. Some chimeric VLP vaccines have been used in clinical trials including the anti-HIV p17/p24: Ty VLP, the nicotine-Qb VLP, the anti-influenza A M2-HBcAg VLP vaccine, the anti-Ang II Qb VLP, and the HBcAg VLPs displaying malaria epitopes (Shirbaghaee and Bolhassani, 2016;Hill et al, 2018). The most common covalent bond was designed by the heterobifunctional chemical cross-linkers with amine and sulfhydryl-reactive arms (Shirbaghaee and Bolhassani, 2016;Hill et al, 2018).…”

Section: Vlps As Delivery Systemsmentioning

confidence: 99%

Improvements in chemical carriers of proteins and peptides

Bolhassani

2019

Cell Biology International

Self Cite

View full text Add to dashboard Cite

The successful intracellular delivery of biologically active proteins and peptides plays an important role for therapeutic applications. Indeed, protein/peptide delivery could overcome some problems of gene therapy, for example, controlling the expression levels and the integration of transgene into the host cell genome. Thus, protein/peptide drug delivery showed a promising and safe approach for treatment of cancer and infectious diseases. Due to the unique physical and chemical properties of proteins, their production (e.g., isolation, purification & formulation) and delivery represented significant challenges in pharmaceutical studies. Modification in the structural moieties of these protein/peptide drugs could improve their solubility, stability, crystallinity, lipophilicity, enzymatic susceptibility and targetability, and subsequently, therapies and cures against various diseases. Using the structural modification of protein/peptide, their delivery provided overall higher success rates including high specificity, high activity, bioreactivity and safety. Recently, biotechnological and pharmaceutical companies have tried to find novel techniques for the modifications and improve delivery systems/carriers. However, each carrier has its own benefits and drawbacks, and an appropriate carrier is often established by the physicochemical properties of protein or peptide, the ideal route of injection, and clinical characteristics of therapy. In this review, an attempt was made to give an overview on the chemical carriers for proteins and peptides as well as the recent advances in this field.

show abstract

Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems

Cited by 113 publications

References 208 publications

Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Identification of genes and pathways in human antigen‐presenting cell subsets in response to polio vaccine by bioinformatical analysis

Improvements in chemical carriers of proteins and peptides

Contact Info

Product

Resources

About